Issues related to prescription drug value, including H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; and implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including H.R. 2882, FY2024 Further Consolidated Appropriations Act. Issues related to the 340B program.
2025 · 1st Quarter (Jan 1 - Mar 31)
GENENTECH, INC.
Filed by MARSHALL & POPP, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 21, 2025
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- MARSHALL & POPP, LLC
- Client
- GENENTECH, INC.
- Filing UUID
- 22d93953-581d-44d7-9983-26b7b144abf7
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to tariff and trade policy.
Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.
Literal federal measure citations: H.Con.Res. 14, S.Con.Res. 7
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.